信迪利单抗联合FOLFOX4方案在胃癌根治术后辅助化疗中的应用效果探讨  

Discussion on the Application Effect of Sintilimab Combined with FOLFOX4 Regimen in Adjuvant Chemotherapy After Radical Gastrectomy for Gastric Cancer

作　　者：原园 夏金[1] YUAN Yuan;XIA Jin(Oncologgyy Department,Anyang Tumor Hospital,Anyang 455100,China)

机构地区：[1]河南省安阳市肿瘤医院肿瘤内科,河南安阳455100

出　　处：《临床医学工程》2023年第12期1707-1708,共2页Clinical Medicine & Engineering

摘　　要：目的探讨信迪利单抗联合FOLFOX4方案在胃癌根治术后辅助化疗中的应用效果。方法82例行胃癌根治术的患者随机分为两组。术后,常规组应用FOLFOX4方案进行化疗,观察组应用信迪利单抗联合FOLFOX4方案进行化疗。比较两组的临床疗效、血清肿瘤标记物及生活质量。结果观察组的ORR、DCR分别为85.37%和95.12%,高于常规组的53.66%和78.05%(P<0.05)。治疗后,观察组的CA199、CEA、TSGF水平均低于常规组,EORTC QLQ-STO22评分高于常规组(P<0.05)。结论信迪利单抗联合FOLFOX4方案在胃癌根治术后辅助化疗中可有效降低患者的血清肿瘤标记物水平,提高患者生活质量。Objective To explore the application effect of sintilimab combined with FOLFOX4 regimen in adjuvant chemotherapy afer radical gastrectomy for gastric cancer.Methods 82 patients who underwent radical gastrectomy for gastric cancer were randomly divided into two groups.After surgery,the conventional group was treated with FOLFOX4 regimen for chemotherapy,and the observation group was treated with sintilimab combined with FOLFOX4 regimen for chemotherapy.The clinical efficacy,serum tumor markers and quality of life were compared between the two groups.Results The ORR and DCR in the observation group were 85.37%and 95.12%,respectively,higher than 53.66%and 78.05%in the conventional group(P<0.05).After treatment,the levels of CA199,CEA and TSGF in the observation group were lower than those in the conventional group,and the EORTC QLQ-STO22 score was higher than that in the conventional group(P<0.05).Conclusions Sintilimab combined with FOLFOX4 regimen in adjuvant chemotherapy after radical gastrectomy for gastric cancer can effectively reduce the levels of serum tumor markers and improve the quality of life of patients.

关 键 词：信迪利单抗 FOLFOX4方案 胃癌根治术 血清肿瘤标记物 

分 类 号：R735.2[医药卫生—肿瘤]